Big Biopharma Trails Behind The Market: JP Morgan’s 2025 Outlook on Eli Lilly, Merck, and More

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. Latest Ratings for LLY Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Mizuho Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for LLY…

Read More